GNLX Stock Analysis: Buy, Sell, or Hold?
GNLX - Genelux Corporation Common Stock
$2.85
-0.07 (-2.40%)
▼
5d:
-5.94%
30d:
-2.4%
90d:
+17.77%
HOLD
LOW Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When GNLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GNLX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: GNLX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: GNLX is currently trading at $2.85, which is considered oversold relative to its 30-day fair value range of $2.88 to $3.02.
Technical Outlook: Technically, GNLX is in a uptrend. The price is currently testing key support at $2.86. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $17.50 (+514.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GNLX is in a uptrend. The price is currently testing key support at $2.86. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $17.50 (+514.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.88 -
$3.02
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 514.0% below Wall St target ($17.50)
- CAUTION: Recommendation downgraded due to -5.9% 5-day decline
Trading Range Analysis
30-Day Trading Range
$2.88 -
$3.02
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.46
(16.2%)
Support & Resistance Levels
Support Level
$2.86
Resistance Level
$3.16
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.74
Wall Street Target
$17.50
(+514.0%)
Revenue Growth (YoY)
-95.3%
Share & Embed Analysis
Last updated: June 24, 2026 5:23 PM ET
Data refreshes hourly during market hours. Next update: 6:23 PM
Data refreshes hourly during market hours. Next update: 6:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GNLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
John Thomas
SELL
10000 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 61 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 60 BUY |
